Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

GTx's Toremifene 80 Mg Increased Bone Mineral Density In Multiple Clinically Relevant Subpopulations Of Prostate Cancer Patients
GTx, Inc. (Nasdaq: GTXI) announced the presentation of data demonstrating that toremifene 80 mg treatment compared to placebo increased bone mineral density (BMD) in multiple clinically relevant subpopulations of men with prostate cancer on androgen deprivation therapy (ADT). The data, an analysis of results of the recent Phase III clinical trial evaluating toremifene 80 mg for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer, were presented yesterday at the 2009 Annual Meeting of the American Society of Clinical Oncology.

Alzheimer's Disease Is The Focus Of TBSI Annual Neuroscience Symposium
Brazos Valley residents, neuroscience researchers, and interested clinicians will each have opportunities to hear from internationally recognized researchers on the topic of aging and Alzheimer"s Disease during the Texas Brain and Spine Institute"s Third Annual Neuroscience Symposium on September 3 and 4. This year"s symposium will consist of an evening of public presentations aimed at helping local residents, Alzheimer"s patients, and their family members better understand early signs of the disease and ways to reduce your risk. The Friday afternoon session will feature a clinical presentation for health providers and researchers.
News of the day
FDA Approves Feraheme™ To Treat Iron Deficiency Anemia In Adult Chronic Kidney Disease Patients
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Feraheme™ (ferumoxytol) Injection for intravenous (IV) use as an iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. The recommended dose of Feraheme is an initial 510 mg IV injection followed by a second 510 mg IV injection three to eight days later. Feraheme should be administered as an undiluted IV injection delivered at a rate of up to 1 mL/sec (30 mg/sec). The recommended Feraheme dose may be readministered to patients with persistent or recurrent iron deficiency anemia.
Mental Health

Free Mammograms Available Through Minnesota Department Of Health - Newly Enrolled Women Will Also Receive A $20 Bonus

The Minnesota Department of Health (MDH) will offer free mammograms through a televised phone bank on FOX 9 KMSP-TV in Minneapolis on Thursday, June 25, 2009. The phone bank will air during the 5 p.m., 5:30 p.m., 9 p.m. and 10 p.m. newscasts. The mammograms are offered through the Sage Screening Program, a state and federally funded program that provides free breast and cervical cancer screenings to uninsured and underinsured women age 40 and older. Newly enrolled women in the program will also receive $20 for being screened, which has been shown to increase screening rates. Messages stressing the importance of detecting breast cancer early and encouraging women to take advantage of the screening program will also run throughout the campaign. MDH"s toll-free number, 1-888-6-HEALTH will be answered from 8 a.m. to 10:35 p.m. on June 25 and 8 a.m. - 5 p.m. all other weekdays. Voice messages can be left anytime outside of these hours. Through this event, MDH hopes to make more women in Minnesota aware of this free program. "We think many women are not receiving these life-saving screening tests because they have no health insurance or their insurance has deductibles or co-payments they cannot meet. Sage can help," said Jonathan Slater, chief of Cancer Control at MDH. Sage has a network of more than 400 local health care providers statewide, and has served nearly 114,000 women since 1991. Approximately 1,400 women have been diagnosed and treated for breast and cervical cancer through the Sage program. This year, it is estimated that 3,500 Minnesotan women will be diagnosed with breast cancer and approximately 650 Minnesota women will die from the disease. Annual mammography has been reported to reduce breast cancer deaths in women age 40 and older by detecting the disease in its earliest stages when it is most easily treated. Women seeking eligibility information about the free mammography program-or women who want to make an appointment for a free mammogram-should call Sage at 1-888-6-HEALTH (1-888-643-2584). Women living in neighboring states or whose incomes exceed Sage"s guidelines, should call the American Cancer Society at 1-800-227-2345 to learn of other free and low-cost programs. For more information, visit http://www.MNSage.com. Minnesota Department of Health


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009